Skip to main content
Clinical Trials/NCT05261620
NCT05261620CompletedNot Applicable

W.I.S.E.-Wine Implementation for Surgical Recovery Enhancement

IRCCS San Raffaele1 site in 1 country132 target enrollmentStarted: December 12, 2022Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
132
Locations
1
Primary Endpoint
Number of participants consuming red wine after surgery showing improved health perception status assessed with the Mental Health Index (MHI) of the Short Form-36 Health Survey questionnaire

Study Overview

Brief Summary

This is a monocenter, prospective randomized clinical trial. The study aims to investigate whether moderate consumption of red wine (1 unit at lunch and 1 unit at dinner) for 30 days after surgery could improve the quality of life (QoL) and health perception status of the patient, without increasing the morbidity and the toxicity related to the surgery.

Detailed Description

Participants are randomized to receive either the standard of care (SoC - no alcohol assumption) (Control Arm) or the standard of care plus wine-controlled intake (Experimental Arm). All participants are candidates for surgery and habitual consumers of alcohol-containing beverages (7-21 alcohol-containing beverages per week) with a body mass index between 18 and 30 kg/m2.

Control Arm subjects adhere to diet free of any alcohol-containing beverages, as normally recommended by surgeons in their clinical practice.

Subjects assigned to the Experimental Arm adhere to usual diet, but were instructed to "Western prudent" dietary principles of the Lyon Diet Heart study, which is the reference in terms of cardiovascular protection, to avoid supplementation of multivitamin, minerals or probiotics, to not drink more than 2 cups of coffee, black or green tea per day and to supervise the intake of food rich in phenolic compounds through providing a list of suggested foods. Subjects will be randomly assigned to consume exclusively during meals one glass (around 150 ml at lunch and 150 ml at dinner) of red wine containing ethanol (˜13% EtOH v/v) with a high content of phenolic compounds (800 mg of Gallic acid equivalent) both for woman and men. Total polyphenolic contents and antioxidant activity (Folin-Ciocalteu method with calibration curve in gallic acid), antioxidant/radical scavenger capacity [DPPH (2,2-diphenyl-1-picrylhydrazyl) test] and phenolic profiles [HPLC (High Performance Liquid Chromatography)/DAD (diode-array detector) /ESI-MS (Electrospray Ionisation Mass Spectrometry) analysis] will be performed for wine selection for the clinical trial. The wine administered for the study purposes will be chosen from a series of wines that will be proposed by the sponsor of the study. The wine with the best polyphenolic and antioxidant properties will be chosen to be administered to the enrolled patients.

For both randomized groups, SoC plus W.I.S.E and SoC only, in order to assess participant's alcohol consumption, a trained psychologist will administer the AUDIT questionnaire specific for alcoholic drinks and a qualitative interview to patients. Frequency of intake is scheduled and each participant will be allowed to drink up to a single unit of wine at lunch and a single unit of red wine at dinner per day from the first post-operative day, during all the hospital stay, and for the next 30 days

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •18 years-old or older
  • •Candidate to surgery
  • •Willing to follow the protocol
  • •Signed informed consent

Exclusion Criteria

  • •Severe Chronic Kidney Disease (eGFR<30)
  • •Severe liver disease (Child-Pugh B or C)
  • •Severe heart failure (NYHA Classes III-IV)
  • •body mass index lower than 18 or higher than 30 kg/m2
  • •Pregnant woman
  • •Teetotal subjects
  • •History of alcohol abuse evaluated through AUDIT questionnaire and qualitative interview by a psychologist
  • •Higher than moderate alcohol intake consumers (more than 25 g of alcohol per day for women and 40 g of alcohol per day for men)
  • •Type I diabetes
  • •Severe respiratory diseases like chronic obstructive pulmonary disease (GOLD classes III-IV)
  • •Neurological diseases such as Alzheimer's, Parkinson's, fibromyalgia or multiple sclerosis.

Arms & Interventions

SoC

No Intervention

Control Arm subjects adhere to diet free of any alcohol-containing beverages, as normally recommended by surgeons in their clinical practice

SoC + WISE

Experimental

Candidates for surgery and habitual consumers of alcohol-containing beverages (7-21 alcohol-containing beverages per week) with a body mass index between 18 and 30 kg/m2. Subjects assigned to the Experimental Arm will be assigned to consume exclusively during meals one glass (around 150 ml at lunch and 150 ml at dinner) of red wine containing ethanol (˜13% EtOH v/v) with a high content of phenolic compounds (800 mg of Gallic acid equivalent).

Intervention: red wine (Dietary Supplement)

Outcomes

Primary Outcomes

Number of participants consuming red wine after surgery showing improved health perception status assessed with the Mental Health Index (MHI) of the Short Form-36 Health Survey questionnaire

Time Frame: 30 days

Health perception status measured using the Mental Health Index (MHI) of the Short Form-36 Health Survey

Secondary Outcomes

  • Number of Participants consuming red wine with a change in blood oxidative stress markers assessed using ORAC (Oxygen Radical Absorbance Capacity) tests(30 days)
  • Number of Participants consuming red wine experiencing hospital readmissions after surgery(30 days)
  • Number of Participants consuming red wine With post-operative complications assessed with Clavien-Dindo classification(30 days)
  • Number of male Participants consuming red wine with change in sexual perceptions after surgery using IIEF questionnaire(30 days)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Umberto Capitanio

Head of the Kidney Tumor Research Unit

IRCCS San Raffaele

Study Sites (1)

Loading locations...

Similar Trials